01301nas a2200241 4500008004100000022001400041245005300055210005200108260007500160300001200235490000600247520057000253653001000823653001300833653001400846653000900860100002500869700002300894700001600917700002500933700002000958856008100978 2013 eng d a1862-834600aGlycated proteome: from reaction to intervention0 aGlycated proteome from reaction to intervention aPOSTFACH 101161, 69451 WEINHEIM, GERMANYbWILEY-V C H VERLAG GMBHcJAN a155-1700 v73 a

Glycation, a nonenzymatic reaction between reducing sugars and proteins, is a proteome wide phenomenon, predominantly observed in diabetes due to hyperglycemia. Glycated proteome of plasma, kidney, lens, and brain are implicated in the pathogenesis of various diseases, including diabetic complications, neurodegenerative diseases, cancer, and aging. This review discusses the strategies to characterize protein glycation, its functional implications in different diseases, and intervention strategies to protect the deleterious effects of protein glycation.

10aaging10aDiabetes10aGlycation10aRAGE1 aKulkarni, Mahesh, J.1 aKorwar, Arvind, M.1 aMary, Sheon1 aBhonsle, Hemangi, S.1 aGiri, Ashok, P. uhttps://library.ncl.res.in/content/glycated-proteome-reaction-intervention-000644nas a2200157 4500008004100000245012600041210006900167260000800236300001600244490000700260100001900267700002500286700002500311700002500336856012500361 2016 eng d00aGlycation induces conformational changes in Amyloid-? peptide and enhances its aggregation propensity: molecular insights0 aGlycation induces conformational changes in Amyloid peptide and  cOCT a31446-314580 v181 aJana, Asis, K.1 aBatkulwar, Kedar, B.1 aKulkarni, Mahesh, J.1 aSengupta, Neelanjana uhttps://library.ncl.res.in/content/glycation-induces-conformational-changes-amyloid-peptide-and-enhances-its-aggregation02880nas a2200193 4500008004100000245017800041210006900219260000800288300001200296490000800308520208800316100002102404700002402425700002402449700002102473700003902494700002502533856012802558 2017 eng d00aGlycation inhibitors extend yeast chronological lifespan by reducing advanced glycation end products and by back regulation of proteins involved in mitochondrial respiration0 aGlycation inhibitors extend yeast chronological lifespan by redu cMAR a104-1120 v1563 aAdvanced Glycation End products (AGEs) are implicated in aging process. Thus, reducing AGEs by using glycation inhibitors may help in attenuating the aging process. In this study using Saccharomyces cerevisiae yeast system, we show that Aminoguanidine (AMG), a well-known glycation inhibitor, decreases the AGE modification of proteins in non-calorie restriction (NR) (2% glucose) and extends chronological lifespan (CLS) similar to that of calorie restriction (CR) condition (0.5% glucose). Proteomic analysis revealed that AMG back regulates the expression of differentially expressed proteins especially those involved in mitochondrial respiration in NR condition, suggesting that it switches metabolism from fermentation to respiration, mimicking CR. AMG induced back regulation of differentially expressed proteins could be possibly due to its chemical effect or indirectly by glycation inhibition. To delineate this, Metformin (MET), a structural analog of AMG and a mild glycation inhibitor and Hydralazine (HYD), another potent glycation inhibitor but not structural analog of AMG were used. HYD was more effective than MET in mimicking AMG suggesting that glycation inhibition was responsible for restoration of differentially expressed proteins. Thus glycation inhibitors particularly AMG, HYD and MET extend yeast CLS by reducing AGEs, modulating the expression of proteins involved in mitochondrial respiration and possibly by scavenging glucose. Significance: This study reports the role of glycation in aging process. In the non-caloric restriction condition, carbohydrates such as glucose promote protein glycation and reduce CLS. While, the inhibitors of glycation such as AMC, HYD, MET mimic the caloric restriction condition by back regulating deregulated proteins involved in mitochondria( respiration which could facilitate shift of metabolism from fermentation to respiration and extend yeast CLS. These findings suggest that glycation inhibitors can be potential molecules that can be used in management of aging. (C) 2017 Elsevier B.V. All rights reserved.1 aKazi, Rubina, S.1 aBanarjee, Reema, M.1 aDeshmukh, Arati, B.1 aPatil, Gouri, V.1 aJagadeeshaprasad, Mashanipalya, G.1 aKulkarni, Mahesh, J. uhttps://library.ncl.res.in/content/glycation-inhibitors-extend-yeast-chronological-lifespan-reducing-advanced-glycation-end02850nas a2200181 4500008004100000245011200041210006900153260000800222520215600230100001602386700002002402700002902422700001402451700002102465700002502486700002502511856013202536 2019 eng d00aGlycation of glucose sensitive lysine residues K36, K438 and K549 of albumin is associated with prediabetes0 aGlycation of glucose sensitive lysine residues K36 K438 and K549 cAUG3 a

Prediabetes is a risk factor for the development of diabetes. Early diagnosis of prediabetes may prevent the onset and progression of diabetes and its associated complications. Therefore, this study aimed at the identification of novel markers for efficient prediction of prediabetes. In this pursuit, we have evaluated the ability of glycated peptides of albumin in predicting prediabetes. Glycated peptides of in vitro glycated albumin were characterized by data dependent acquisition and parallel reaction monitoring using LC-HRMS. Amongst 14 glycated peptides characterized in vitro, four peptides, particularly, FK(CML)DLGEENFK, K(AML)VPQVSTPTLVEVSR, K(CML)VPQVSTPTLVEVSR, and K(AML)QTALVELVK, corresponding to 3 glucose sensitive lysine residues K36, K438, and K549, respectively showed significantly higher abundance in prediabetes than control. Additionally, the abundance of three of these peptides, namely K(AML)QTALVELVK, K(CML)VPQVSTPTLVEVSR and FK(CML)DLGEENFK was >1.8-fold in prediabetes, which was significantly higher than the differences observed for FBG, PPG, and HbA1c. Further, the four glycated peptides showed a significant correlation with FBG, PPG, HbA1c, triglycerides, VLDL, and HDL. This study supports that glycated peptides of glucose sensitive lysine residues K36, K438 and K549 of albumin could be potentially useful markers for prediction of prediabetes. SIGNIFICANCE: Undiagnosed prediabetes may lead to diabetes and associated complications. This study reports targeted quantification of four glycated peptides particulary FK(CML)DLGEENFK, K(AML)VPQVSTPTLVEVSR, K(CML)VPQVSTPTLVEVSR, and K(AML)QTALVELVK, corresponding to 3 glucose sensitive lysine residues K36, K438 and K549 respectively by parallel reaction monitoring in healthy and prediabetic subjects. These peptides showed significantly higher abundance in prediabetes than healthy subjects, and showed significant correlation with various clinical parameters including FBG, PPG, HbA1c, and altered lipid profile. Therefore, together these four peptides constitute a panel of markers that can be useful for prediction of prediabetes.

1 aRathore, R.1 aSonwane, B., P.1 aJagadeeshaprasad, M., G.1 aKahar, S.1 aSanthakumari, B.1 aUnnikrishnan, A., G.1 aKulkarni, Mahesh, J. uhttps://library.ncl.res.in/content/glycation-glucose-sensitive-lysine-residues-k36-k438-and-k549-albumin-associated-prediabetes